Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HT-101 Injection and/or HT-102 Injection in Patients With Chronic Hepatitis B Virus Infection

NCT07183306 is registered in ClinicalTrials.gov with Suzhou HepaThera Biotech Co., Ltd. as lead sponsor.

NCT NCT07183306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07183306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HT-101 Injection and/or HT-102 Injection in Patients With Chronic Hepatitis B Virus Infection
Lead sponsor
Suzhou HepaThera Biotech Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 30, 2024
Completion date
May 3, 2027
Enrollment
86 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b